Search Results 11-20 of 1199 for ���������������������katalk:PC53���200%������ ��������� ������ ���������������������������������
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
... 53:37-06:00</lastmod><xhtml:link rel="alternate" hreflang="ar" href="https://www.mayoclinic.org/ar/tests-procedures/aortic-root-surgery/about/pac-20383396 ...
This is a phase I study of PICN alone and in combination with carboplatin and consisting of 2 sequential parts. Part A will characterize the pharmacokinetic ...
A Study to Evaluate APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) · Overview · Participation eligibility · Participating ...
The investigators want to find out what effects, good and/or bad, CAMP has on patients and their metastatic castration-resistant prostate cancer. Participation ...
The purpose of this study is to evaluate the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced ...
A relative risk of 100% means your risk is twice as high as that of someone without that risk factor. A 200% relative risk means that you are three times as ...
The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure during induction chemotherapy for patients with ...
A Study to Evaluate the Effectiveness, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Pediatric Patients with Developmental and/or Epileptic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.